Quality & complianceOfficial

Denmark flags Frovatriptan Viatris supply problems expected to last until January 2028

🇩🇰 DKMA · Fri 13 Nov 2026

The Danish Medicines Agency reports manufacturing problems affecting Viatris ApS's frovatriptan 2.5 mg film-coated tablets, with disruption expected from mid-May 2026 to the end of January 2028.

The Danish Medicines Agency (DKMA) has published a supply notice for Frovatriptan "Viatris" 2.5 mg film-coated tablets, marketed in Denmark by Viatris ApS. It says there are current problems with supply of the product.

The agency gives production problems as the cause. The expected period of disruption runs from mid-May 2026 to the end of January 2028, a span of roughly 20 months. The notice was first published on 11 May 2026 and last updated on 13 November 2026.

The product contains the active substance frovatriptan, as frovatriptan succinate monohydrate, and carries ATC code N02CC07. Frovatriptan is a triptan used in migraine, although the DKMA notice does not describe the indication.

The notice does not name alternative products or give detail on the nature of the production problems. DKMA directs enquiries about the current status to the company. The item sits within the agency's Meddelelser om forsyning af medicin, its list of medicine supply notices.

What it means for your team

  • Supply teams should plan for a prolonged gap: the notified period runs to the end of January 2028.
  • Pharmacovigilance and medical information teams may wish to prepare for questions from prescribers and patients about availability.
  • Market-access and pharmacy contacts should ask Viatris ApS directly for the current status, as DKMA says it cannot provide it.
  • The notice names no alternatives, so any substitution planning will need to be worked out separately.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →